Co-Authors
This is a "connection" page, showing publications co-authored by Haruhito Sugiyama and Norio Ohmagari.
Connection Strength
2.628
-
Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan. J Infect. 2021 08; 83(2):237-279.
Score: 0.237
-
Investigator initiated clinical trial of remdesivir for the treatment of COVID-19 in Japan. Glob Health Med. 2021 Apr 30; 3(2):62-66.
Score: 0.236
-
Consistency of the results of rapid serological tests for SARS-CoV-2 among healthcare workers in a large national hospital in Tokyo, Japan. Glob Health Med. 2021 Apr 30; 3(2):90-94.
Score: 0.236
-
Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan. J Infect. 2021 04; 82(4):e1-e3.
Score: 0.232
-
Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial. JMIR Res Protoc. 2020 Dec 31; 9(12):e23830.
Score: 0.230
-
Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19. J Clin Apher. 2021 Jun; 36(3):313-321.
Score: 0.230
-
Successful Recovery from COVID-19-associated Acute Respiratory Failure with Polymyxin B-immobilized Fiber Column-direct Hemoperfusion. Intern Med. 2020 Oct 01; 59(19):2405-2408.
Score: 0.225
-
Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers. Crit Care Explor. 2020 Aug; 2(8):e0170.
Score: 0.224
-
COVID-19 can suddenly become severe: a case series from Tokyo, Japan. Glob Health Med. 2020 Jun 30; 2(3):174-177.
Score: 0.222
-
SARS-CoV-2 Screening Test for Japanese Returnees From Wuhan, China, January 2020. Open Forum Infect Dis. 2020 Jul; 7(7):ofaa243.
Score: 0.222
-
SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medicine. Glob Health Med. 2020 Apr 30; 2(2):107-111.
Score: 0.220
-
Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Sci Rep. 2021 03 10; 11(1):5563.
Score: 0.058
-
Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. Gene. 2021 Jan 15; 766:145145.
Score: 0.056